Poxel S.A. presented the results of the 12-week, randomized, controlled Phase 2a trial in 120 presumed NASH patients, with or without T2DM, which evaluated three dosing regimens of PXL770, Poxel’s lead direct AMP kinase activator, versus placebo. The results showed that treatment with PXL770 at 500 mg QD resulted in significant reductions in mean liver fat content and alanine transaminase (ALT) levels (vs. baseline). Greater effects were observed in patients with coexisting Type 2 diabetes (T2D, 41-47% of each group): -27% reduction in liver fat content at 500 mg QD vs. baseline; an increase in the proportion of responders (>30% reduction in liver fat); dose-responsive and significant mean decreases in ALT and aspartate transaminase (AST) levels vs. placebo. In the T2D patients, significant placebo-adjusted decreases were observed in fasting plasma glucose and HbA1c (-0.64%) despite well-controlled baseline fasting levels (121-144 mg/dL and 6.6-7.1%, respectively), along with improvements in commonly used fasting indices of insulin sensitivity (HOMA-IR and QUICKI scores). PXL770 was well tolerated with an acceptable safety profile.